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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: Previous studies suggested that mesenchymal stem cells may ameliorate
fibrogenesis through the inhibition of hepatic stellate cells (HSCs) activation. This study aimed
to investigate whether adipose derived mesenchymal stem cells (ADSCs) could modulate the
activation of HSCs and contribute to the recovery of liver fibrogenesis.
Methods: ADSCs and HSCs were isolated from Sprague-Dawley rats and co-cultured using a
transwells insert. Cell proliferation, apoptosis and smooth muscle a-actin (a-SMA) expression
in HSCs were examined. Rats were injected with CCl4 to induce liver fibrogenesis. After injec-
tion of ADSCs through portal vein, the rats were examined for pathological changes in the liver.
a-SMA expression and hydroxyproline content in the liver and serum levels of collagen III and
hyaluronic acid was detected.
Results: After co-culturing for 72 h, the proliferation and activation of HSCs was inhibited by
ADSCs and the apoptosis of HSCs was promoted by ADSCs. Transplantation of ADSCs inhibited
liver fibrogenesis in the rats.
Conclusion: ADSCs inhibit the proliferation and activation of HSCs in vitro and inhibit liver fi-
brogenesis in rat model, suggesting the potential application of ADSCs in liver fibrogenesis
therapy.
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ADSCs inhibit HSCs activation 131IntroductionIt is estimated that over 100 million people suffer from liver
fibrosis worldwide. Although liver fibrosis and the resulting
cirrhosis are caused by a variety of etiologic agents,
including chronic viral hepatitis, alcohol toxicity, auto-
immune disease, and hereditary metabolic disorders, it is
now generally accepted that a central pathologic mecha-
nism underlying liver fibrosis is the generation and pro-
liferation of smooth muscle a-actin (a-SMA) positive
myofibroblasts of periportal and perisinusoidal origin that
arise as a consequence of the activation of hepatic stellate
cells (HSCs) and other cell types, such as periportal fibro-
blasts.1,2 As the main complication of chronic liver damage,
liver fibrosis is a wound healing process characterized by
the accumulation of extracellular matrix (ECM) proteins in
the liver. HSCs are critically involved in the development of
liver fibrosis because they are responsible for the excessive
deposition of ECM proteins in the liver.3,4
Major progress has been made recently in the pre-
vention, diagnosis, and treatment of liver fibrosis, including
the application of liver transplantation and artificial livers.5
However, the increasing number of patients suffering from
liver disease and the limited availability of suitable donor
livers present substantial problems. As a result, the
development of alternative, effective antifibrotic therapies
to replace liver transplantation is urgently needed. Bone
marrow mesenchymal stem cells (MSCs) are multipotential
cells that reside within the bone marrow and can be
induced to differentiate into various components of the
marrow microenvironment, such as bone, adipose, and
stromal tissues, depending on the conditions.6 Recent
studies have shown that MSCs from bone marrow can alle-
viate fibrosis formation through the inhibition of HSC acti-
vation, suggesting that stem cell transplantation is a
promising therapeutic approach for combating liver
fibrosis.7e10
Unfortunately, the isolation of MSCs is a highly invasive
and painful procedure, and the frequency of MSCs in bone
marrow is relatively low. Therefore, alternative cell
sources that overcome the disadvantages of bone
marrow-derived stem cells are clearly needed. Adipose
tissue-derived mesenchymal stem cells (ADSCs) are sim-
ilar to MSCs in that they also have properties of stem
cells, such as self renewal, extensive proliferation
capacity, and the ability to differentiate into multiple
cell lineages.11,12 More importantly, ADSCs have unique
advantages compared to MSCs: they can be easily har-
vested from subcutaneous fat tissue using a safe and
conventional liposuction procedure, the frequency of
ADSCs in adipose tissue is much higher than that of MSCs
in the bone marrow, and ADSCs proliferate markedly
faster than MSCs.13,14 However, whether ADSCs can be
exploited for cell transplantation to reduce liver fibrosis
remains largely unknown. The apparent advantages of
ADSCs led us to investigate whether they may be an ideal
transplantable cell type to treat liver fibrosis. In the
present study, we transplanted ADSCs into rats with
carbon tetrachloride (CCl4)-induced hepatic cirrhosis and
showed that ADSCs could ameliorate liver fibrogenesis by
modulating HSCs.Materials and methods
Animals
Six week-old inbred Sprague-Dawley rats with an initial
body weight of 150e200 g were obtained from the Animal
Experimental Center of Wenzhou Medical College and
housed in a standard animal laboratory. They were kept at
25C with a 12-hour light/dark cycle and allowed standard
chow and water ad libitum until the time of the study. The
study protocol and animal care were approved by the
Animal Care and Use Committee of Wenzhou Medical
College, and conformed to the Guide for the Care and Use
of Laboratory Animals by the National Institutes of Health
(NIH Publication No. 80-23).
Culture of rat liver cells
Buffalo rat liver cells (BRLs) were obtained from the
Longwan Experimental Center of Wenzhou Medical College
and cultured in L-DMEM (HyClone; Thermo Scientific,
Waltham, MA, USA) medium supplemented with 10% fetal
bovine serum (FBS, Gibco, Carlsbad, CA, USA) in a humidi-
fied atmosphere with 5% CO2 at 37C. The medium was
changed every 2e3 days.
Isolation and culture of adipose tissue-derived
mesenchymal stem cells
One male rat was anesthetized with ether. The subcuta-
neous adipose tissue was harvested from the rat and
carefully dissected. The tissue was digested using collage-
nase type IV (1 mg/mL; Sigma, St Louis, MO, USA) and then
dissociated mechanically by shaking at 37C for 1 hour. The
suspension was then centrifuged at 200g for 5 minutes. The
pellet cells were resuspended in DMEM supplemented with
10% FBS (Gibco) and cultured in a humidified atmosphere
with 5% CO2 at 37
C. The medium was changed every 2e3
days. The cells were passaged when they grew to 80%
confluence. The third to fifth generations of the passaged
cells were collected and subjected to flow cytometry
analysis using the ADSC-specific markers CD73, CD90,
and CD45.
Isolation and culture of hepatic stellate cells (HSCs)
Rat HSCs were isolated and grown in primary culture as
previously described.15 After isolation by density gradient
centrifugation, cells were grown in L-DMEM supplemented
with 10% FBS at 37C in 5% CO2. The medium was changed
after 48 hours. After 5e7 days, the HSCs grew rapidly and
the medium was changed every 2e3 days thereafter.
Transwell co-culture of ADSCs and HSCs
ADSCs were cultured in apical compartments of transwells
(transwell insert 0.4 mm; Millipore, Billerica, MA, USA) with
HSCs grown in the basal compartment of a 6-well plate
(Millipore). ADSCs were seeded onto the upper layer of
transwells at a density of 2  104 cells/well and were not in
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third generation culture were seeded onto the lower layer
of transwells at a density of 2  104 cells/well. All cells
were cultured in L-DMEM supplemented with 10% FBS at
37C in 5% CO2. In addition, BRLs were seeded instead of
ADSCs onto the upper layer as a negative control, or no cells
were seeded onto the upper layer as a blank control. After
culturing the cells for 72 hours, the morphology of the cells
grown in transwells was assessed under an inverted phase
contrast microscope. The cell proliferation was analyzed
using the CCK-8 kit (Dojindo, Kumamoto, Japan) following
the manufacturer’s instructions. The absorption (A) was
read at 450 nm using a spectrophotometer. The inhibition
rate (%) of HSC proliferation was calculated as: 1  (A of
control  A of ADSCs)/(A of control  A of HSCs)  100%.
The experiments were performed in triplicate and
repeated twice.
Establishment of rat model of liver fibrogenesis
To establish a model of liver fibrogenesis, male rats (weight
250e300 g) were selected and 1.5 mL/kg CCl4 (diluted 1:1
in olive oil) was injected subcutaneously twice a week for
10e12 weeks. The hydroxyproline content in the liver was
assayed using the chloramines-T method. Serum levels of
collagen III and hyaluronic acid were tested by radio-
immunoassay following the manufacturer’s instructions.
Transplantation of ADSCs
CCl4-induced rat liver fibrogenesis models were divided into
two groups: the ADSCs treatment group and the control
group (nZ 10 each). The rats were anesthetized with 2 g/L
pentobarbital sodium and the abdomen was incised to
identify the portal vein to the liver. Rats in the ADSC group
were injected through the portal vein with 5  106 ADSCs
suspended in 1.5 mL PBS. Rats in the control group were
injected with 1.5 mL PBS. The injection was performed
once every 2 weeks. After 4 weeks, the rats in both groups
were sacrificed and subjected to hematoxylin and eosin
(H&E) and Masson staining to observe the pathological
changes in the liver sections.
Western blot analysis
HSCs co-cultured with ADSCs or control HSCs were har-
vested and lysed in lysis buffer (20 mM Tris, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 0.1% NP40, 0.5% sodium deoxy-
cholate, 1 mM phenylmethylsulfonyl fluoride, and gabexate
mesilate) on ice for 30 minutes. The lysate was centrifuged
at 12,000g at 4C for 15 minutes and the supernatant was
collected. Equal amounts of protein from the supernatant
were loaded onto SDS-polyacrylamide gels and transferred
onto nitrocellulose membranes. The membranes were
blocked with 5% nonfat milk in TBS for 1 hour and incubated
with primary antibodies against a-SMA (1:100, Southern
Biotech, Birmingham, AL, USA) or glyceraldehyde 3-
phosphate dehydrogenase (Santa Cruz Biotech, Santa
Cruz, CA, USA) at 4C overnight. After three washes with
TBS-T, the membranes were incubated with secondary
horseradish peroxidase-coupled antibodies (1:30,000,Southern Biotech) at 37C for 1 hour. The protein bands
were visualized using enhanced chemiluminescence
reagents (Pierce; Thermo Scientific) and were quantified by
image analysis with a Gel-pro Analyzer (ckvision, Beijing,
China). Glyceraldehyde 3-phosphate dehydrogenase was
used as a loading control.
Determination of the concentration of cytokines by
enzyme-linked immunosorbent assay
ADSCs and BRLs were seeded in 6-well plates at a density of
2  105 cells/well. After culturing the cells in L-DMEM
supplemented with 10% FBS for 72 hours, the medium was
collected and the secretion of cytokines from ADSCs or BRLs
into the medium was detected using enzyme-linked
immunosorbent assay (ELISA) kits for hepatic growth
factor (HGF), transforming growth factor (TGFb1), nerve
growth factor (NGF), and interleukin-10 (IL-10; all kits
obtained from R&D, Minneapolis, MN, USA) following the
manufacturer’s instructions.
Immunocytochemical staining of a-SMA in HSCs
HSCs were cultured on coverslips and fixed with 4% paraf-
ormaldehyde. An a-SMA antibody (1:200 dilution; Boshide,
Wuhan, China), biotin-labeled secondary antibody, horse-
radish peroxidase-conjugated streptavidin, and dia-
minobenzidine were added sequentially according to the
standard protocol. Brown staining indicated the expression
of a-SMA.
Flow cytometry analysis of apoptosis
After co-culturing ADSCs and HSCs for 72 hours, the cells
were collected by digestion with EDTA-free trypsin (Invi-
trogen, USA). The cell pellet was washed with PBS twice,
and approximately 2  105 cells were resuspended in 200 mL
Annexin V binding buffer (BD Biosciences, Franklin Lakes,
NJ, USA). The cells were stained with 5 ml Annexin V FITC
(BD Biosciences) for 20 minutes at 4C in the dark. The
reaction was stopped by the addition of 5 mL propidium
iodide, and the samples were then incubated for 5 minutes
at 4C in the dark. The samples were subjected to flow
cytometry analysis within 1 hour. The assay was performed
in triplicate and repeated twice.
Immunohistochemical staining
After HSC transplantation, rat liver tissues were fixed in
40 g/L paraformaldehyde and then embedded in paraffin
wax. Subsequently, 4-mm thick serial sections of the tissues
were cut. The sections were washed carefully with 0.01 M
phosphate buffered saline (PBS) three times (10 minutes
each), and then blocked with 2% goat serum in 0.01 M
PBS containing 0.3% Triton X-100 (PBS-X) for 1 hour at room
temperature. The sections were incubated at 4C overnight
with an anti-desmin rabbit antibody (1:200 dilution).
The slides were then processed using an immunohis-
tochemical staining kit (Vector, Burlingame, CA, USA). After
visualizing the reaction with the DAB chromogen, the slides
were counterstained with hematoxylin and covered with a
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antibodies were replaced with PBS.
TUNEL assay
After ADSC transplantation, rat liver tissues were fixed in
40 g/L paraformaldehyde and then embedded in paraffin
wax. Subsequently, 4-mm thick serial sections of the tissues
were cut and the apoptosis of HSCs was detected by ter-
minal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) using a kit (Roche, Grenzach-Wyhlen, Germany)
following the manufacturer’s protocol.
Statistical analysis
The experiments’ data were expressed as mean  standard
deviation. The differences between different groups were
analyzed by one way ANOVA using SPSS16.0 software (SPSS,
Inc., Chicago, IL, USA) and p < 0.05 was considered
significant.
Results
Isolation and characterization of ADSCs
Approximately 1e2  106 ADSCs were harvested from
1e2 mg of rat adipose tissue. The proportion of freshly
isolated living ADSCs was >95%, as defined by trypan blue
staining. ADSCs adhered to the plate wall after 4e6 hours
and developed a spin phenotype after 48 h. The ADSCs grew
very fast after 5e6 days and were passaged when they grewFigure 1 (A) The phenotype of adipose-derived mesenchymal ste
Magnification 200. (B) The expression of CD45, CD73 and CD90 into 80% confluence (Fig. 1). In addition, we performed flow
cytometry analysis on the isolated ADSCs to detect the
expression of ADSCs markers. The results showed that the
isolated ADSCs exhibited high expression of CD73 and CD90
but low expression of CD45, consistent with recent
report.16
Isolation and characterization of HSCs
Approximately 1e2  107 HSCs were harvested from each
rat. The proportion of freshly isolated living HSCs was more
than 95%, as defined by trypan blue staining. Under an
inverted phase-contrast microscope, the freshly isolated
cells were round and full of lipid droplets in the cytoplasm.
When stimulated at 328 nm wavelength, most HSCs had
blue or green intrinsic autofluorescence due to the pres-
ence of vitamin A-rich lipid droplets (Fig. 2A). After
culturing the cells for 2e3 days, the cells adhered to the
wall of the plate, and after 5-7 d of growing the cells in
culture, they extended and presented an asteroid pheno-
type (Fig. 2).
ADSCs co-culture inhibits the expression of a-SMA
in HSCs
After co-culturing HSCs with ADSCs for 72 hours, the num-
ber of HSCs expressing a-SMA was much lower compared to
HSCs co-cultured with BRLs, as detected by immunocy-
tochemistry (Fig. 2B). These results were confirmed by
western blot analysis. The results showed that the level of
a-SMA was lower in HSCs co-cultured with ADSCs than in
HSCs co-cultured with BRLs (Fig. 2C).m cells isolated from the rat adipose tissue (on the first day).
isolated adipose-derived mesenchymal stem cells.
Figure 2 (A) The phenotype of primary hepatic stellate cells (HSCs) isolated from the rat liver (on the second day). Magnification
400. Co-culturing adipose-derived mesenchymal stem cells (ADSCs) with HSCs inhibits the expression of smooth muscle a-actin
(a-SMA) in HSCs. (B) Immunocytochemical staining of a-SMA in HSCs co-cultured with buffalo rat liver cells (left panel) or with
ADSCs (right panel) for 72 hours. Magnification 100. (C) Western blots showing the protein level of a-SMA in HSCs co-cultured with
buffalo rat liver cells or ADSCs (p < 0.05). Representative blots were shown from three independent experiments with similar
results. Glyceraldehyde 3-phosphate dehydrogenase served as a loading control.
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proliferation and promotes apoptosis of HSCs
The CCK-8 assay showed that after HSCs and ADSCs were
co-cultured for 72 hours, the proliferation of HSCs was
significantly inhibited (1.209  0.117) compared to HSCs co-
cultured with BRLs (1.424  0.013) or HSCs cultured alone
(2.172  0.107; Fig. 3A). Flow cytometry analysis showed
that the apoptosis rate of HSCs was significantly higher in
the ADSCs þ HSCs group (4.600  0.794%) than in the
BRLs þ HSCs (2.817  0.225%) and HSCs groups
(2.496  0.115%; Fig. 3B). Taken together, these results
demonstrate that co-culturing ADSCs and HSCs inhibits the
proliferation and promotes apoptosis of HSCs.ADSCs transplantation alleviates rat liver
fibrogenesis in vivo
CCl4 induced liver fibrogenesis in rats, as determined by
H&E and Masson staining (Fig. 4AeC). After transplantation
of ADSCs into CCl4-injured rats, the hepatic engraftment
rate was approximately 20%, and the mortality rate of rats
receiving ADSC injection was approximately 30%. Trans-
plantation of ADSCs into the liver reduced the fibrotic area.
The transplantation of ADSCs alleviated rat liver fibro-
genesis, was confirmed by the expression of collagen I and
a-SMA, which are two proteins that are highly expressed
during liver fibrogenesis. Western blot analysis showed that
the transplantation of ADSCs reduced the expression ofcollagen I and a-SMA in the liver (Fig. 4D). In addition, the
transplantation of ADSCs led to a reduced hydroxyproline
level in the liver and reduced collagen III and hyaluronic
acid levels in the serum of CCl4-induced rats, although the
levels of these indicators of liver fibrogenesis were still
higher in rats transplanted with ADSCs than in normal rats
(Table 1). Collectively, these data suggest that the trans-
plantation of ADSCs can ameliorate the formation of liver
fibrosis in rats exposed to CCl4.
In addition, immunohistochemical staining and a TUNEL
assay detected the proliferation and apoptosis of HSCs
in vivo, respectively. The results showed that in the control
group, the number of desmin positive and TUNEL positive
HSCs was 45  11 and 11  3, respectively; however, in the
treatment group, the HSC numbers were 31  7 and 17  5,
respectively (Fig. 5).These data suggest that trans-
plantation of ADSCs into rat liver inhibits proliferation and
promotes apoptosis of HSCs, which is consistent with the
in vitro results.
Cytokines secreted by ADSCs and HSCs
Since ADSCs prevent the proliferation and promote the
apoptosis of HSCs without direct contact to HSCs, it was
assumed that the cytokines secreted by ADSCs may help
mediate the effects observed. Therefore, the concen-
tration of cytokines secreted into the medium was exam-
ined by ELISA. The results showed that ADSCs secreted high
levels of HGF and low levels of NGF and TGFb1 compared to
BRLs (Table 2).
Figure 3 Co-culturing adipose-derived mesenchymal stem cells with hepatic stellate cells (HSCs) inhibits proliferation and
promotes apoptosis in HSCs. (A) After co-culturing HSCs with buffalo rat liver cells (BRLs) or HSCs for 72 hours, the proliferation of
HSCs was examined using the CCK-8 assay. The proliferation of HSCs was significantly inhibited compared to HSCs co-cultured with
BRLs or HSCs cultured alone (1.209  0.117 vs. 1.424  0.013 vs. 2.172  0.107, p < 0.05). (B) The apoptosis of HSCs was detected
by Annexin V-PI double staining and flow cytometry analysis. The apoptosis rate of HSCs was significantly higher in the adipose-
derived mesenchymal stem cells þ HSCs group than in the BRLs þ HSCs group or HSCs group. All data were expressed as
mean  standard deviation derived from three independent experiments performed in triplicate.
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HGF, NGF, TGFb1, and IL-10 in the rats after ADSC trans-
plantation. The results showed that, compared to the con-
trol group, HGF levels were higher while NGF and TGFb1
levels were lower in the treatment group (p< 0.05; Table 3).
The IL-10 levels were not significantly different between
control and treatment groups. These results are consistent
with the in vitro secretion of cytokines by ADSCs.
Discussion
The incidence of hepatitis is high in China. Hepatitis can
develop into liver cirrhosis, which can further cause liverfailure or liver cancer, and is the leading cause of death in
these patients. Therefore, the early detection and pre-
vention of hepatic fibrosis is very important. The current
clinical treatment for liver fibrosis is surgery, which cannot
reverse the process of liver fibrogenesis. Furthermore, liver
transplantation has many disadvantages, such as a shortage
of donors, high cost, and trauma during operation. In recent
years, a large number of basic experimental studies and
clinical research have demonstrated that stem cell trans-
plantation is a promising approach for the treatment of
liver fibrosis.16e20
HSCs are mesenchymal cells that are critically involved
in liver fibrosis. In pathological conditions, such as liver
Figure 4 Transplantation of ADSCs alleviates rat liver fibrogenesis in vivo. (AeC) Pathological examination of liver tissues from
different groups of experimental rats: (A) hematoxylin and eosin (H&E) staining of liver sections in rats fed with a normal diet for 12
weeks; B. H&E staining and Masson Staining of liver sections in control group (rats fed with a CCl4 diet for 12 weeks); (C) H&E
staining and Masson Staining of liver sections in treatment group (rats fed with a CCl4 diet þ ADSCs for 12 weeks). (D) Western blots
showing the protein levels of a-SMA and collagen I in the liver tissues (p < 0.05). Representative blots were shown from three
independent experiments with similar results. Glyceraldehyde 3-phosphate dehydrogenase served as a loading control.
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activated and proliferate rapidly. The secretion of compo-
nents of the ECM from HSCs to the liver is an important
factor of liver fibrosis. MSCs have been shown to inhibit the
activation of HSCs and contribute to the recovery of liver
fibrogenesis in animal models.7e10 However, the application
of MSCs is limited by the availability of MSCs. Since ADSCs
were first isolated in 2001,21 an increasing body of evidence
has shown that ADSCs have many advantages compared to
MSCs and are better suited for applications in tissue
engineering.22,23
Most of the previous studies on stem cell trans-
plantation for the treatment of liver fibrogenesis have
concentrated on the differentiation of stem cells into
liver cells, which may improve liver function. Given thatTable 1 Mean  standard deviation hepatic hydroxyproline lev
groups of rats.
Group Hyaluronic acid (mg/L)
Normal 81.23  5.97
Treatment 178.8  28.2
Control 282.3  18.7
p <0.05the activation and proliferation of HSCs are important for
the development of liver fibrosis,24 we wondered
whether ADSCs inhibit liver fibrosis by regulating the
proliferation and activation of HSCs. Therefore, we co-
cultured ADSCs and HSCs in 6-well plates through a
transwell insert and found that ADSCs could inhibit the
activation and proliferation of HSCs, suggesting that
these effects were mediated not via direct cell-to-cell
contact, but rather through the factors secreted into
the medium. Indeed, the ELISA results showed that ADSCs
secreted large amounts of HGF but very low levels of
TGFb1 into the medium. These results are consistent
with a previous study reporting that high HGF and low
TGFb1 exhibited beneficial effects on the recovery from
liver cirrhosis.25els and serum laminin and hyaluronic acid levels in different
Collagen III (mg/L) Hydroxyproline (mg/L)
9.33  1.18 212.8  9.4
21.74  3.30 325.8  28.2
35.28  3.31 458.4  38.1
<0.05 <0.05
Figure 5 Immunohistochemical staining of rat liver. (A,B) Anti-desmin staining of the liver section: (A) Treatment group;
(B) Control group. The arrows indicate desmin positive cells. (C,D) TUNEL staining of the liver section: (C) Treatment group;
(D) Control group. The arrows indicate desmin/TUNEL double positive cells. Magnification 400.
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that ADSCs promote the apoptosis of HSCs. Taken together,
these data suggest that the cytokines secreted by ADSCs
may modulate the activation, proliferation, and apoptosis
of HSCs, which ultimately leads to the reduction of HSCs
and the recovery of liver fibrogenesis.
To validate these in vitro data, we employed a CCl4-
induced liver cirrhosis rat model and transplanted ADSCs
into the liver. The results showed that the liver trans-
plantation group had mild fibrosis compared to the control
group. Measurement of biochemical parameters also dem-
onstrated that ADSCs ameliorated the fibrosis. In addition,
we performed immunohistochemical staining and a TUNEL
assay to detect the proliferation and apoptosis of HSCs
in vivo, respectively. The results showed that trans-
plantation of ADSCs into rat liver inhibited the proliferation
and promotes apoptosis of HSCs. In addition, an ELISA assay
showed that compared to the control group, HGF levels
were higher, while NGF and TGF-b1 levels were lower in the
treatment group, which is consistent with the in vitroTable 2 Mean  standard deviation concentrations of hepatic g
growth factor (TGFb1), and interleukin-10 (IL-10) secreted into t
Cells HGF (ng/L) NGF (ng/L)
ADSCs 74.93  2.54 5.46  0.45
BRLs 58.08  2.44 14.68  0.95
p <0.05 >0.05
ADSCs Z adipose-derived mesenchymal stem cells; BRLs Z buffalo rasecretion of cytokines by ADSCs. Collectively, these in vivo
data complement the in vitro data and provide evidence
that ADSCs help in the recovery of liver fibrogenesis through
indirect modulation of HSCs, instead of direct differ-
entiation into functional hepatocytes. The positive effects
of ADSCs subsequently promote liver regeneration.
Although we have shown that ADSCs can markedly inhibit
liver cirrhosis in a rat model, it is important to point out the
limitations of the present study. We only examined the
effects of ADSC transplantation on liver fibrogenesis
4 weeks after the transplantation. Future studies with
multiple points of time and over a longer period of time are
required to determine the dosage and for how long the
transplanted ADSCs can inhibit liver fibrogenesis. Moreover,
future studies should determine the time point at which the
transplanted ADSCs exhibit optimal therapeutic effects. In
addition, the tumorigenicity and allograft rejection of the
transplanted ADSCs need be addressed in further studies to
pave the way for the clinical application of ADSCs in the
treatment of liver fibrogenesis.rowth factor (HGF), nerve growth factor (NGF), transforming
he medium.
TGFb1 (ng/L) IL-10 (ng/l)
10.65  0.46 23.82  0.92
136.06  1.51 27.73  0.22
<0.01 >0.05
t liver cells.
Table 3 Mean  standard deviation concentrations of hepatic growth factor (HGF), nerve growth factor (NGF), transforming
growth factor (TGFb1), and interleukin-10 (IL-10) in rat serum.
Group HGF (ng/L) NGF (ng/L) TGFb1 (ng/L) IL-10 (ng/L)
Control 71.8  5.4 72.9  4.5 195.3  14.8 56.9  3.2
Treatment 193.5  17.5 43.4  3.3 73.1  3.6 52.7  3.5
Normal 21.7  3.6 34.7  2.0 39.5  2.0 24.7  1.6
p <0.05 <0.05 <0.05 >0.05
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